Bot D Yakubu¹, Olaniru B Olumide² and Bigwan T Yanan¹*

¹Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, University of Jos, Plateau State, Nigeria
²Department of Chemical Pathology, Jos University Teaching Hospital Jos, Plateau State, Nigeria

*Corresponding Author: Bigwan T Yanan, Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, University of Jos, Plateau State, Nigeria.

Received: November 07, 2022; Published: February 16, 2022

Abstract

&A case study was conducted to screen Prostate-specific antigen levels of 50 elderly Men and understand their risk for Prostate cancer, the study was conducted at Church of Christ in Nations (COCIN) LCC Bukuru and its environs. Those included were asymptomatic elderly males of age 50 years and above at COCIN LCC Bukuru and environs, those who filled the consent form and agreed to be part of the studies and those that have not been previously diagnosed with prostate cancer or any form of cancer. Those excluded from this study were Men below the age of 50 years at COCIN LCC Bukuru and environs, those who did not fill the consent form or did not agree to be part of the studies, those previously diagnosed with prostate cancer or any form of cancer, Men that were sick. 8(16%) participants were diagnosed with PSA levels above the normal range, and 42(84%) were below the normal range. A blood sample (5 ml) was collected via venipuncture and the serum was assayed for PSA using chemiluminescence immunoassay method.

Based on the body mass index of the target population, individuals under 18.5 (underweight) were 2(4%), individuals from 18.5-25 (normal weight) were 24(48%), individuals from 25-30 (overweight) were 16(32%), individuals at 30 and above (obese) were 8(16%). Based on the demographic characteristics, the number of participants in the age group 50-59 had 28(56%) individuals; 60-69 had 11(22%) individuals; 70-79 had 6(12%) individuals; 80 years and above 5(10%) age in the study. The mean ± SD of PSA levels of men based on body mass index (BMI) of fifty (50) participants were screened. Individuals under 18.5 were 2(4%) had 4.81 ± 5.95, participants between 18.5 - 25 were 24(48%) had 2.62 ± 4.63, individuals between 25 - 30 were 16(32%) had 2.06 ± 2.75 and participants above 30 BMI were 8(16%) had 2.39 ± 2.15, with a mean of 2.49 ± 3.74 and a P-value of 0.808.

Keywords: Prostate Specific Antigen; Screening; Men; Bukuru

References

1. Balk SP., et al. “Biology of Prostate-Specific Antigen”. Journal of Clinical Oncology2 (2003): 383-391.
2. Abbiyesuku FM., et al. “Prostate Specific Antigen in Nigeria”. African Journal of Medicine and Medical Science (2000): 97-100.
3. Rao AR., et al. “The Discovery of Prostate-Specific Antigen”. British Journal of Urology International1 (2008): 5-10.
4. Ferlay J., et al. “Cancer Incidence and Mortality Worldwide: Sources, Methods, and Major Patterns in GLOBOCAN”. International Journal of Cancer5 (2015): 359-386.
5. Moyar VA. "U.S. Preventive Services Task Force. Final Recommendation Statement Prostate Cancer Screening”. Annals of Internal Medicine 157 (2012): 120 34.
6. Smith RA., et al. “American Cancer Society. American Cancer Society guidelines for the early detection of cancer”. Cancer Journal for Clinicians 53 (2003): 27-43.
7. Abuadas MH., et al. “Predictors of Prostate Cancer Screening Intention among Older Men in Jordan”. International Journal of Urology1 (2017): 31-41.
8. Theisen C. "Predicting the Future: Projections Help Researchers Allocate Resources”. Journal National Cancer Institute 12 (2003): 846-848.
9. Ogundele SO and Ikuerowo SO. "A Survey of the Awareness of Prostate Cancer and its Screening Among Men Attending the Outpatient Clinics of a Tertiary Health Center in Lagos”. Nigerian Journal of Surgery, Publication of Nigerian Surgical Research Society 2 (2015): 115-118.
10. Stephanie EB., et al. “Body Mass Index in Relation to Serum Prostate-Specific Antigen Levels and Prostate Cancer Risk”. International Journal of Cancer1 (2016): 50-57.
11. Cao Y and Ma J. "Body Mass Index, Prostate Cancer-Specific Mortality, and Biochemical Recurrence: A Systematic Review and Meta-Analysis”. Cancer Prevention Research4 (2011): 486-501.
12. Mandong BM., et al. “Malignant Diseases in Jos”. Annals of African Medicine2 (2015): 49-53.
13. Jibril OB., et al. “National Library of Medicine”. African Health Journal8 (2019): 445-561.
14. Banez LL., et al. “Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer”. JAMA 19 (2007): 2275-2280.
15. Prince MM., et al. “Body Mass index, prostate-specific antigen and digital rectal examination findings among participants in a prostrate cancer screening clinic”. Urology5 (2008): 787-791.
16. Culp S and Porter M. "The effect of obesity and lower serum prostate-specific antigen levels on prostate cancer screening results in American men”. BJU International10 (2009): 1457-1461.
17. Jonathan LW., et al. “The effect of demographic and clinical factors on the relationship between BMI and PSA levels”. The Prostrate15 (2011): 1631-1637.
18. Chang SL., et al. “Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition examination survey.”. Journal of Clinical Oncology 25 (2010): 3951-3957.
19. H. O. (WHO) (2015).
20. Okolo CA., et al. “Correlation of Serum PSA and Gleason Score in Nigerian men with Prostate Cancer”. African Journal of Urology 14 (2008): 15-22.

Citation

Citation: Bigwan T Yanan., et al. “Demographic Implications of Serum Prostate-Specific Antigen Screening Among Men in Bukuru and Environs" Acta Scientific Cancer Biology 7.1 (2023): 02-06.

Copyright

Copyright: © 2022 Bigwan T Yanan., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.